Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.06 - $5.58 $30,600 - $55,800
-10,000 Reduced 66.67%
5,000 $16,000
Q1 2024

May 15, 2024

BUY
$2.03 - $6.59 $28,216 - $91,601
13,900 Added 1263.64%
15,000 $63,000
Q4 2023

Feb 14, 2024

BUY
$1.4 - $2.09 $1,540 - $2,299
1,100 New
1,100 $1,000

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $141M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.